safe where might Kevin. for are company. thank hope your matter you to interest you you all our of I and Thanks in you be. Welcome all no
been to Teva's into communities. I to to COVID-XX. you our production, have I have elements for focusing just insights financials Before I response business continuity, the and go the and our four we sourcing some address employees give where chosen like the first into quarter
every of also the need It's just not the serve XXX million because been day. the medicines but secure to force around business of need patients we because paramount of of essential that business continuity in
wanted We towards R&D to product secure our have the progress launches. could that minimize on new impact and also programs we
In instruments upgradation we a going our implemented. digital being lot seeing of process of the have keeping commercial been
in in instrumental ways not job been to sales E-detailing force keep been of have I’m any different COVID-XX. to we have new a related of doing report lot losses order We effective. to also had communication that seeing the
We have kept operational. everything
A essential the course thank could products facilities to all uninterrupted for report big happy part materials and we been been finished facilities secure challenging to of worldwide. do have across chain many times. that in fantastic live our medicines. production. they our difficulties this of very basically to have employees sourcing operational raw supply stay all the of adequate I we for have to from able doing would securing medicines demand safe our demand and global of up that for like I meet job network chain our supply inventories we the is We to open had our am our and to an our operation and in customers despite remain all
been For consideration. safety our paramount employees has
anybody safe report We secure due no been a work. to being to had and have rig going We healthy able of to environment. infected
and all up from requirements local course work both guidelines both to based on environment. We stay also in healthy a is and global own many side This and secure many, authorities. implemented have local precautions from living keep and operational order our to of strict
through different also near supporting in different but working global treatments have governments It's parts we of near tablets approved healthcare communities of the and our also offices been different been both investigational millions to treatments for our many, the organizations, world. for systems different healthcare communities for many supplying with important the us both international support organizations factories, local but communities our already
changing We take and that to those we now secure our to demand in we products could have for portfolio. to finished also products demand live production both into are schedules been that securing consideration API more products in up our that the have
the industry Let's On the the industry positives availability research brief of One a realizes in working to risks clear various I of essential are together And slide. COVID-XX. just being modalities COVID-XX positive to in is new of related importance order course next to pharmaceutical vaccines, related think treatments and some give overview some a positive needed will industry, the I now is it society this for move the of of you to doing industry slide, the supplying try very to secure ensure for treatment medicines. that governments pharmaceutical to new are but that both treatments, it’s clearly in for. sought of also the for medications and
for worldwide changed. existing medicines not demand underlying and this has is an and There new also
to new the So despite all our slow the COVID-XX so hasn't products. different because underlying health for being changed on this of is everybody for demand we there focused have and same population the remember situation that broad the
do the said I in worldwide. to what we in change will ways future our there the be will communicating new we digital seen permanent of products promotion As sales and before capabilities have extent show our new of way force, the a only us
not clinical results as seeing material the have see hoping months in We trials coming are coming on to through planned. impact and any ongoing we our
of materials countries, predominantly significant very supply. than concentrated a know materials the our risks. more to course these especially there manufacturing global couple have are Europe. and network API raw raw I'm factories with of some also finished that most report in own of factories in that for is in that concentrated much We western goods happy API are in However, of and and countries and XX all eastern we are few terms
sales in quarters. patient There's overstocking the products a month predict to exactly the the It's these is of strong-strong of might for to healthcare that a our also lower that risk and it interaction in this the at It's to a of lead and hard lead related demand risk reduced patient we level, a patient coming clear but risk. demand this some seen that to slower March professionals physical of these and uptake course force a could products. have new products sales not is the and could lead there fact to specific seen between yet, our quite we've months something
lockdown also trials will and in quite how clinics hospitals on we it's the delays will last of countries. clear to delayed the of individual the been and depend planning some that And be have initiate then will that clinical long
a and with we and working diligently have risks. overall try avoid the we some that So the positives course we some of dynamic pursue to we secure situation positives risks and to
strong and by but $X.X to was back will move out $X.X get next a lower cost also a helped The of by and by came in and I by ongoing all billion. products result for revenues demand non-GAAP we If demand also rationalization COVID-XX our will the slide, lockdowns, the I to. partly billion now was but at EBITDA positive March the optimization higher the influenced show the high products. key by that and cost affected revenues, This our lower OTC that to for programs was We move financials. underlying generics the also
$X.XX at but at We We about to came million out see do we came EPS $X steady cash billion. basis a at level ongoing flow and saw $X I've $X.XX. and billion around repeat generation the billion. yearly have get is $XXX many times strong running per above swings GAAP non-GAAP just slightly a here on the that will what $X out quarter. EPS later, above Eli into at some The said cash a
leads reduction of debt. an to also ongoing This net the
it down $XX.X quarter we million reduction in This and are $XXX was billion. to now
very We changes. at have looking been the carefully
from changes. to both development So and the the the all leads the look our sort This us when and also upsides reconfirm from general outlook. and downsides ups business COVID-XX and all but and at we of downs
will remains So our more outlook in that Eli unchanged. into detail get
had positive If We've nice we some then in it. and the had U.S. developments. the we at the just launched auto-injector AJOVY look we've approved business
launches CGRP the the which has We were in of UK AJOVY Europe in We in anti- approval countries. have for NICE positive. got very prevention XX more was migraine first product seen now
one launched U.S., the in biosimilar more We've HERZUMA.
full pattern in BENDEKA an We until in December the had in have designation launched and respiratory portfolio Eagle that saw which look the now the patents partners orphan we BENDEKA means XXXX. win stands stand orphan ruling also until drug which gives And court which designation digitized we BENDEKA/TREANDA in drug products months on the our XX, had forward U.S. then the and will positive we last the a us digihalers coming the U.S. these product launching market to in means
remember slide, the that and I've plan at that trough Teva then flat we is I told since bottom. ago. a the revenue earnings. to years move probably be pretty of that If than in XXXX also next presented I for trough would a here restructuring said terms two you you more the
biosimilar have of very of strong due have mentioned. trough seeing earnings underlying we it here, not and increase little lot there product is more and OTC to quarter several and also in launches a strong in QX, the it's increase America as really in sold the very probably in and ‘XX So when March you're revenue the that's I strong very we we a first start and seeing that a generics did a getting Rituxan, dramatic but with generic that will because Europe bit in quarter being out including an I a say North you're had to than be
if of and things, out earnings. you are the in improvement we've and I passed the normalize trough, things are both seeing revenues just that sort we and seeing can to a bottom confirms we trough of that the we of slow So even all but these been seeing try you are take
apart about this like point If AJOVY. business nice the from picture these many slide the next to to we our our then describes and of talked times for drivers we've are generic the this before very what business auto-injector. growth AJOVY and strong key turn I to AUSTEDO
Now device, the use also very the of the I'll in the business and Germany benefits been I of what nice benefits get said to this launched what U.S. the patients auto-injector for has and development. in back terms also and in and it's as been to easy are slick just just and launched
the total you in see scripts. AUSTEDO. how very we a and development slide positive to you to see that count patient The graph on quarter can we're or here move steady, next doing If very the can for the left script that's a then we have a
also see did more it's as stock bit heading we the look steady that hole the saw continues sales the I you QX effect we're the having a small can is QX million the swings of trend underlying a and If we tell bit confident in just year. AUSTEDO $XXX bumpy. we at this and donut between revenues you little for but goal U.S. scripts are of as the then of underlying and but that a the in trend QX in
So in AUSTEDO disease very also strong in dyskinesia. of in course tardive Huntington's Korea both in development and
the flat of slide, move be. This AJOVY, course can for to want how we normalized actually how for is count to has it we and If while. see you count a you the gone script it here TRx the next weekly not can quite see
of It also is that anti-CGRP to our around auto-injector. with despite quarterly and not for the auto-injector XX%-XX% NBRx has, that approval an doctor's two and both not a the a available both we basically and nicely which have this up the two the an and can branch the our profile did saw us in decline. delayed acting product because of the we product see is with were auto-injector long out down. action safety offices being That meant result in the it we Share since to products long it then how version the losing unfortunate weekly fact went came due auto-injector You benefits its despite the new the the getting have
a confident can the and eventually share for launched high the an that. long-term hopes our that in of is target I'm I just auto-injector end this we new-to-brand both increase to aim new-to-brand and total share Now we'll do with very see XX% have year and we the and also
been seeing just more as mentioned approved European also We're Canada. we've in launches and I
are this keeping very I'm positive $XXX for we target confident that year for AJOVY we of see a will development million. at unchanged So and AJOVY sale an
now and program program this If even both; we you all no target a operational stopped all move improvement started you that next on we the we margin finished things and a then that improvement the of program XX% what's the the first is is the that here because the program model. I happening to remember have you probably in an program I operating ask no well. finished of and to COVID-XX to last happening different restructuring and we slide running can gross this program to all we and long-term the surpassed see talked we doing organizational ask since the the new chain, is already procurement, quarter you program, might with network, about We're have not elements supply margin tell very excellence, might quarter
We manufacturing have reorganized our entire operation.
program. the So we The quarter full exceptionally good. is swing numbers the for first are in with
XX% sustainable target the operating program the is at an at but say that So end do of is that this level for achievable and that going what yet they're still you we indicate XXXX for. are the that target margin they is not could
And to next like slide long-term target. to if then our I we financial the just to whatsoever it no clear there's go that change absolutely make
are talked the just margin about I We can target. reach income this. operating We confident. very XX%
a to earnings to We way to of a to This that ratio what net are we generate is only below pay debt use because XX% course That's of of is and have XXXX. keep of is That's the informed we debt and doing on doing. the the down cash course target. cash X end also debt what debt. have We'll it to to reduce and EBITDA at going to still have target we're above doing. be our as consequence huge
through will the So financial with of these who go Eli details. words I'll hand over to more
